GlassScriptPhysician profile
Terrisa S Ha
NPI 1083675516
$15,981.38
in general payments reported to CMS, 2019-2025
46 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,654 · 2020: $2,118 · 2021: $4,237 · 2022: $1,626 · 2023: $1,319 · 2024: $1,546 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,257 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,257.46 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,832.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,802.25 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,440.33 | 2019-2025 | Repatha, Evenity, Prolia |
| Biohaven Pharmaceuticals, INC. | $1,333.36 | 2020-2021 | |
| Lilly USA, LLC | $1,146.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $992.10 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.46 | 2019-2025 | Synjardy, Jardiance |
| Abbvie INC. | $806.37 | 2019-2025 | |
| Amarin Pharma, INC. | $577.36 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $563.65 | 2019-2025 | Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $324.87 | 2019-2021 | |
| Glaxosmithkline, LLC. | $319.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $271.89 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.87 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $225.29 | 2022-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $209.40 | 2021-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $188.69 | 2019-2024 | |
| Bausch Health US, LLC | $188.02 | 2019-2025 | Aplenzin, Wellbutrin |
| Kowa Pharmaceuticals America, INC. | $187.73 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Insmed, INC. | $186.73 | 2022-2025 | Arikayce |
| Teva Pharmaceuticals USA, INC. | $179.05 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $177.72 | 2024-2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company LTD. | $171.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $162.45 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $153.29 | 2022-2024 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $134.41 | 2024-2025 | Voquezna |
| Scilex Pharmaceuticals INC. | $131.82 | 2019 | |
| Exact Sciences Corporation | $129.24 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $121.80 | 2023-2025 | Rexulti, Nuedexta |
| Radius Health, INC. | $119.91 | 2019-2025 | Tymlos |
| Astellas Pharma US INC | $109.41 | 2019-2024 | |
| Horizon Therapeutics Plc | $95.48 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $94.96 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $69.30 | 2024 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $66.85 | 2025 | Edarbi |
| Abbott Laboratories | $66.11 | 2022-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $59.70 | 2022 | |
| Mayne Pharma Commercial LLC | $53.74 | 2021-2025 | |
| Currax Pharmaceuticals LLC | $38.98 | 2022-2025 | Contrave |
| Edwards Lifesciences Corporation | $35.54 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Eisai INC. | $24.70 | 2020 | |
| Genentech USA, INC. | $23.84 | 2019 | |
| Exeltis, USA INC. | $23.46 | 2025 | Slynd |
| Ironwood Pharmaceuticals, INC | $21.00 | 2020 | |
| Scynexis, INC. | $18.89 | 2022 | |
| Gilead Sciences, INC. | $16.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrisa Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.